Autres langues Aptose Biosciences Inc. OTC Markets

Actions

APTO.F

CA03835T4081

Produits pharmaceutiques

Marché Fermé - OTC Markets Autres places de cotation 19:03:40 12/06/2026			Varia. 5j.	Varia. 1 janv.
1,612 ^USD	+2,71%		+2,71%	+8,95%

29/05	Aptose Biosciences : le rachat par Hanmi reporté au mois de juin	MT
29/05	Aptose Biosciences annonce un nouveau report de la finalisation de son accord avec Hanmi Pharmaceutical	RE

Autres langues

29/05	Aptose Biosciences Says Acquisition by Hanmi Delayed Until June
29/05	Aptose Biosciences says closing of arrangement with Hanmi Pharmaceutical further delayed
29/05	Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical
13/05	Aptose Biosciences: Q1 Earnings Snapshot
13/05	Aptose Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
13/05	Aptose Biosciences : Reports First Quarter 2026 Results
13/05	Aptose Reports First Quarter 2026 Results
30/04	Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical
01/04	Aptose Biosciences: Q4 Earnings Snapshot
31/03	Aptose Shareholders Approve Acquisition By Hanmi Pharmaceutical in "Go Private" Transaction
31/03	Aptose Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
31/03	Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights
31/03	Aptose Biosciences Inc. Auditor Raises 'Going Concern' Doubt
23/03	Leading independent proxy advisory firm Glass Lewis endorses Aptose plan of arrangement
23/03	Aptose Biosciences Brief: Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement With Hanmi Pharmaceutical
23/03	Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement
20/03	Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote FOR Proposed Plan of Arrangement with Hanmi Pharmaceutical
19/03	Leading independent proxy advisory firm ISS recommends Aptose Biosciences shareholders vote "for" proposed plan of arrangement with Hanmi Pharmaceutical
19/03	Aptose Brief: Independent Proxy Advisory Firm ISS Recommends Aptose Shareholders Vote "FOR" Proposed Plan of Arrangement with Hanmi Pharmaceutical
19/03	Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote “FOR” Proposed Plan of Arrangement with Hanmi Pharmaceutical
24/02	Aptose Biosciences announces amendment to arrangement agreement and details of shareholders meeting
24/02	Aptose Biosciences Announces Amendment to Arrangement Agreement and Details of Postponed Special Meeting of Shareholders
22/12	Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC
19/12	Aptose Biosciences Brief: Announcing Rescheduling of Special Meeting of Holders to OK Acquisition by Hanmi Pending Final Clearance from SEC
19/12	Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC